Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With Chemotherapy and Local Treatment in Non-small Cell Lung Cancer Patients With Brain Metastasis, a Single-arm, Multi-center, Open-labeled Phase II Clinical Trial

NCT04291092 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT04291092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04291092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With Chemotherapy and Local Treatment in Non-small Cell Lung Cancer Patients With Brain Metastasis, a Single-arm, Multi-center, Open-labeled Phase II Clinical Trial
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2020
Completion date
June 30, 2023
Enrollment
63 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, immunotherapy, nsclc stage iv